Press Releases

Information for the media and for our investors

Formycon Publishes Half-Year Results for 2019

Formycon AG has today announced its financial results for the first half of 2019. With a Group turnover of Euro 17,2 million and a period result of Euro -0,7 million Formycon Group's commercial figures were as forcast.

Formycon Reports on Annual General Meeting 2019

Formycons shareholders followed the proposals of the Board of Management and the Supervisory Board and approved all resolutions proposed by the management with large majorities in each case.

Formycon Reports Further Course of Capital Measure

With the agreement dated June 26, 2019, Wendeln & Cie. KG, an asset management company of Mr. Peter Wendeln (anchor shareholder and long-standing member of the Supervisory Board of Formycon AG), acquired all rights from the certificate of subscription as well as the 577,397 shares in Formycon AG from the cash capital increase.

Formycon Publishes Figures for the First Quarter of 2019

The Group sales, including other earnings, as of March 31 of this year amount to EUR 9.5 million. Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to EUR 0.5 million. The operating result (EBIT) as well as the quarterly result totaled around EUR 0.2 Million. The reported sales revenues result from reimbursements for development work in the licensed-out projects or projects developed in partnership. For the 2019 fiscal year, revenues in the amount of approximately EUR 35.0 million are expected at the group level.

Formycon Reports Latest Status of Capital Increase

As of today, totaling EUR 5,000,000.00, have been paid to the company’s capital increase account. The signatory's debt contribution amounting to EUR 12,264,170.30 is therefore still outstanding. The shares have so far not been delivered due to the as yet unsettled payment.

Formycon Reports Successful 2018 Financial Year

The Group's turnover rose compared to last year (Euro 29 million) by 48 percent to around Euro 43 million, exceeding forecasts. The earnings before interest, tax, depreciation and amortization on fixed and immaterial assets (EBITDA) were Euro 8 million (previous year Euro -0.8 million), which is significantly higher than last year’s figure.

Formycon Announces News on Development Portfolio

Formycon has published news on its development portfolio. The FDA submission of FYB201 is expected for the beginning of the fourth quarter of this year. The submission to the European Medicines Agency (EMA) is scheduled for the first quarter of 2020. Also significant progress have been achieved with FYB202 and FYB203.

Strategic Investor M&H Equity AG Subscribes Cash Capital Increase of Euro 17.3 Million

The Swiss company M&H Equity AG from Heerbrugg in the Canton of St. Gallen is a strategic investor with a long-term investment horizon. The funds acquired from the capital increase should be used primarily to develop the company’s own biosimilar products and further increase the value of the pipeline.

Formycon Places Cash Capital Increase of EUR 17.3 Million with Institutional Investor

Strategic investor M&H Equity AG subscribes for a cash capital increase of € 17,264,170.30 million in the context of a private placement with an issue price of 29.90 EUR per share. The funds acquired from the capital increase will be used primarily to develop the company’s own biosimilar products, particularly FYB205.

Formycon Releases Updates on Development Programs and Milestones

For FYB201, new data from the recently completed COLUMBUS-AMD phase III trial in patients with neovascular age-related macular degeneration (nAMD) are available.

Formycon Reports Nine-Month Figures for 2018

The turnover of the Formycon group increased significantly compared with the first nine months of 2017.

Formycon Reports Financial and Operating Results for the First Half Year of 2018

Formycon AG has revealed impressive results for the first half of 2018 both in the development of its product candidates and its business figures. Key milestones were reached on project FYB201, a biosimilar candidate for Lucentis®* (ranibizumab).

Formycon Appoints Development and Production Expert Thomas Siklosi to the Advisory Board

The former board member of Rentschler Biopharma SE is a renowned biotech manager and expert of biologics and biosimilars

Formycon with Significant Growth in Turnover and Earnings in the First Quarter of 2018

Formycon has significantly improved its revenue and earnings in the first quarter of 2018 compared to the same period of the previous year.

Formycon With Successful 2017 Financial Year

Formycon has ended the 2017 financial year successfully and has once again significantly advanced the development of its product candidates.